William Schelman
Hutchmed · HUTCHMED International · HUTCHMED International Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William Schelman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:13 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06291415 · The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)Hutchmed · withdrawn · Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases · study director
- Ph1/Ph2NCT05077384 · Open-label Study of Surufatinib in Japanese PatientsHutchmed · completed · Neuroendocrine Tumors, Non-hematologic Malignancy · study director
- Ph2NCT04579679 · Open-Label Surufatinib in European Patients With NETHutchmed · terminated · Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET · study director
- Ph1/Ph2NCT04577963 · A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsHutchmed · terminated · Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult · study director
- Ph1/Ph2NCT04579757 · Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsHutchmed · terminated · Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors · study chair
- Ph3NCT04322539 · A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerHutchison Medipharma Limited · completed · Metastatic Colorectal Cancer, Metastatic Colon Cancer · study director
- Ph1NCT03251378 · A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersHutchison Medipharma Limited · completed · Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer · study director
- Ph1NCT01233505 · Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · terminated · Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier · principal investigator
- Ph1NCT01217450 · Selumetinib and Cetuximab in Treating Patients With Refractory Solid TumorsNational Cancer Institute (NCI) · completed · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer · principal investigator
- Ph2NCT00356889 · Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsNational Cancer Institute (NCI) · completed · Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)R21CA170876 · NCI · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2012 to 2013 · $153,849 awarded in 2013Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- UW Comprehensive Cancer Center SupportP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · fiscal years 2011 to 2026Named on NCT01233505, NCT01217450
- Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)U01CA062491 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GLENN LIU · fiscal years 2011 to 2013Named on NCT01233505, NCT01217450
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:13 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.Lancet Oncol · 2013445 citationsRCR 11.0
- 323 citationsRCR 26.1
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.J Clin Oncol · 2015161 citationsRCR 4.7
- A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.Oncologist · 201174 citationsRCR 1.9
- First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.Cancer Chemother Pharmacol · 201274 citationsRCR 1.8
- A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.Invest New Drugs · 201538 citationsRCR 1.1
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.Invest New Drugs · 201437 citationsRCR 1.1
- A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.Invest New Drugs · 201436 citationsRCR 1.0
- A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.Cancer Chemother Pharmacol · 200927 citationsRCR 0.8
- A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.Invest New Drugs · 201325 citationsRCR 0.6